Isatou Jagne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isatou Jagne has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Abdoulie Bojang
Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG at LSHTM)
2 shared publications- Anna Roca
Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia
2 shared publications A. Bojang
Medical Research Council Unit, Gambia
1 shared publicationA. Roca
Medical Research Council Unit, Gambia; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
1 shared publicationAminata Cham
Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG at LSHTM)
1 shared publicationB. Camara
Medical Research Council Unit, Gambia
1 shared publication
Latest Publications
- Open Access
Incidence, risk factors and outcomes for neonatal sepsis in The Gambia: Descriptive cohort analysis embedded in a randomised clinical trial
Background: Neonatal sepsis is a major contributor to adverse neonatal outcomes in West Africa. High quality data on risk factors for sepsis in this region is limited, yet important for surveillance, prevention and management of newborns at greatest risk. This study aimed to describe the clinical epidemiology of sepsis for health-facility born neonates in an urban West African setting. Methods: This study comprised secondary data analyses from the Gambian cohort of the PregnAnZI-2 randomised clinical trial. Relatively healthy pregnant women and their offspring who delivered at two urban health facilities were included, with a combination of active and passive surveillance until 28 days. Neonatal sepsis was defined as suspected if clinical and laboratory (abnormal FBC or CRP) criteria were met, and confirmed if blood-culture was positive. A novel conceptual framework informed logistic regression models to identify 1) factors associated with neonatal sepsis and 2) contribution of sepsis towards neonatal mortality. Results: A total of 6515 neonates were included. The health-facility based incidence of neonatal sepsis was 20.2 cases/1000 live births (N=131 cases), predominantly early-onset (Burkholderia cepacia and Staphylococcus aureus the most prevalent bacteria in 24% (7/29) of confirmed sepsis each. Risk factors for sepsis included low 1-minute Apgar score (aOR 13.2, 95% CI 8.40-20.73), pre-labour maternal fever (aOR 5.0, 95% CI 1.15-21.69), easily recognisable congenital malformation (aOR 3.39, 95% CI 1.55-7.38) and low-birth weight (aOR 2.85, 95% CI 1.75-4.65). 40.7% of all neonatal deaths in the cohort occurred in neonates with sepsis, with 40-fold increase in mortality compared to neonates without sepsis (OR: 39.98, 95% CI 22.5 – 71.1). Conclusion: Sepsis, especially early onset, is a major morbidity for health facility born neonates delivered following relatively healthy pregnancy in urban Gambia, with high associated mortality. We identify neonatal phenotypes (low birth weight, newborns with low 1-minute apgar scores, or those with easily recognisable congenital malformations) who may benefit from enhanced postnatal surveillance or antibiotics to prevent or treat neonatal sepsis and reduce neonatal mortality. Trial Registration: NCT03199547: Clinicaltrials.gov . Registered on 23 rd June 2017
Open AccessIncidence, risk factors and outcomes for neonatal sepsis in The Gambia: Descriptive cohort analysis embedded in a randomised clinical trial
Background: Neonatal sepsis is a major contributor to adverse neonatal outcomes in West Africa. High quality data on risk factors for sepsis in this region is limited, yet important for surveillance, prevention and management of newborns at greatest risk. This study aimed to describe the clinical epidemiology of sepsis for health-facility born neonates in an urban West African setting. Methods: This study comprised secondary data analyses from the Gambian cohort of the PregnAnZI-2 randomised clinical trial. Relatively healthy pregnant women and their offspring who delivered at two urban health facilities were included, with a combination of active and passive surveillance until 28 days. Neonatal sepsis was defined as suspected if clinical and laboratory (abnormal FBC or CRP) criteria were met, and confirmed if blood-culture was positive. A novel conceptual framework informed logistic regression models to identify 1) factors associated with neonatal sepsis and 2) contribution of sepsis towards neonatal mortality. Results: A total of 6515 neonates were included. The health-facility based incidence of neonatal sepsis was 20.2 cases/1000 live births (N=131 cases), predominantly early-onset (Burkholderia cepacia and Staphylococcus aureus the most prevalent bacteria in 24% (7/29) of confirmed sepsis each. Risk factors for sepsis included low 1-minute Apgar score (aOR 13.2, 95% CI 8.40-20.73), pre-labour maternal fever (aOR 5.0, 95% CI 1.15-21.69), easily recognisable congenital malformation (aOR 3.39, 95% CI 1.55-7.38) and low-birth weight (aOR 2.85, 95% CI 1.75-4.65). 40.7% of all neonatal deaths in the cohort occurred in neonates with sepsis, with 40-fold increase in mortality compared to neonates without sepsis (OR: 39.98, 95% CI 22.5 – 71.1). Conclusion: Sepsis, especially early onset, is a major morbidity for health facility born neonates delivered following relatively healthy pregnancy in urban Gambia, with high associated mortality. We identify neonatal phenotypes (low birth weight, newborns with low 1-minute apgar scores, or those with easily recognisable congenital malformations) who may benefit from enhanced postnatal surveillance or antibiotics to prevent or treat neonatal sepsis and reduce neonatal mortality. Trial Registration: NCT03199547: Clinicaltrials.gov . Registered on 23 rd June 2017
- Open Access
- 1 April 2018
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 24 (4) , 389-395
Maternal pneumococcal nasopharyngeal carriage and risk factors for neonatal carriage after the introduction of pneumococcal conjugate vaccines in The Gambia
- 1 April 2018
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 24 (4) , 389-395
Open AccessMaternal pneumococcal nasopharyngeal carriage and risk factors for neonatal carriage after the introduction of pneumococcal conjugate vaccines in The Gambia
- Open Access
- 28 March 2018
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 67 (8) , 1191-1197
Long-term Impact of Oral Azithromycin Taken by Gambian Women During Labor on Prevalence and Antibiotic Susceptibility of Streptococcus pneumoniae and Staphylococcus aureus in Their Infants: Follow-up of a Randomized Clinical Trial
Oral azithromycin given to women in labor decreases maternal and neonatal bacterial carriage but increases azithromycin-resistant bacteria during at least 4 weeks following the intervention. We assessed the prevalence of bacterial carriage and azithromycin resistance 12 months after treatment among study infants. Nasopharyngeal swabs (NPSs) were collected between November 2014 and May 2015 from children aged 11–13 months whose mothers had received azithromycin or placebo during labor. Streptococcus pneumoniae and Staphylococcus aureus were isolated using conventional microbiological methods. Antibiotic susceptibility was determined by disk diffusion and confirmed by Etest or VITEK-2. NPSs were collected from 461 children. The prevalence of S. pneumoniae and S. aureus was similar between children from the azithromycin and placebo arms (85.0% vs 82.1%; odds ratio [OR], 1.23 [95% confidence interval {CI}, .73–2.08] for S. pneumoniae and 21.7% vs 21.3%; OR, 1.02 [95% CI, .64–1.64] for S. aureus). Prevalence of azithromycin-resistant S. pneumoniae was similar in both arms (1.8% vs 0.9% in children from the azithromycin and placebo arms, respectively; OR, 2.10 [95% CI, .30–23.38]); resistance to other antibiotics was also similar between arms. For S. aureus, there was no difference in azithromycin resistance between children in the azithromycin (3.1%) and placebo (2.6%) arms (OR, 1.22 [95% CI, .35–4.47]) or resistance to any other antibiotics. The higher prevalence of S. aureus azithromycin resistance observed among women treated during labor and their babies 4 weeks after treatment had waned 12 months after delivery. Azithromycin intervention did not induce other antibiotic resistance to S. pneumoniae or S. aureus. NCT01800942.
- 28 March 2018
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 67 (8) , 1191-1197
Open AccessLong-term Impact of Oral Azithromycin Taken by Gambian Women During Labor on Prevalence and Antibiotic Susceptibility of Streptococcus pneumoniae and Staphylococcus aureus in Their Infants: Follow-up of a Randomized Clinical Trial
Oral azithromycin given to women in labor decreases maternal and neonatal bacterial carriage but increases azithromycin-resistant bacteria during at least 4 weeks following the intervention. We assessed the prevalence of bacterial carriage and azithromycin resistance 12 months after treatment among study infants. Nasopharyngeal swabs (NPSs) were collected between November 2014 and May 2015 from children aged 11–13 months whose mothers had received azithromycin or placebo during labor. Streptococcus pneumoniae and Staphylococcus aureus were isolated using conventional microbiological methods. Antibiotic susceptibility was determined by disk diffusion and confirmed by Etest or VITEK-2. NPSs were collected from 461 children. The prevalence of S. pneumoniae and S. aureus was similar between children from the azithromycin and placebo arms (85.0% vs 82.1%; odds ratio [OR], 1.23 [95% confidence interval {CI}, .73–2.08] for S. pneumoniae and 21.7% vs 21.3%; OR, 1.02 [95% CI, .64–1.64] for S. aureus). Prevalence of azithromycin-resistant S. pneumoniae was similar in both arms (1.8% vs 0.9% in children from the azithromycin and placebo arms, respectively; OR, 2.10 [95% CI, .30–23.38]); resistance to other antibiotics was also similar between arms. For S. aureus, there was no difference in azithromycin resistance between children in the azithromycin (3.1%) and placebo (2.6%) arms (OR, 1.22 [95% CI, .35–4.47]) or resistance to any other antibiotics. The higher prevalence of S. aureus azithromycin resistance observed among women treated during labor and their babies 4 weeks after treatment had waned 12 months after delivery. Azithromycin intervention did not induce other antibiotic resistance to S. pneumoniae or S. aureus. NCT01800942.